Navigation Links
Labopharm's NDA for Novel Trazodone Formulation accepted for review by FDA
Date:11/24/2008

olerated adverse event profile, a very low rate of sexual dysfunction and no weight gain compared to placebo.

MDD is one of the most prevalent central nervous system disorders, affecting more than 120 million people worldwide. In 2007, the global market for antidepressants and related psychiatric drugs was US$19 billion, of which US$12 billion was accounted for by the U.S.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cauti
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. E6 Ventures Invests in Novel Coatings Developer, Diamond Hard Surfaces Ltd
2. Novel imaging technique reveals brain abnormalities that may play key role in ADHD
3. Future Looks Bright For Non-Invasive Diagnosis Of Skin Cancer; Study Shows Novel Light Device Detects Cancerous Lesions From Normal Tissue
4. Novel IBS treatment developed at UB garners $8.5 million for seven-year clinical trial
5. Novel 4-drug combination proves safe for lung cancer treatment
6. Porter Novelli Named Agency of Record for Pharmavite(R) LLC
7. Completely novel action of insulin unveiled
8. Yo Mujer: Woman Escapes from Abusive Marriage in New Spanish-Language Novel
9. Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
10. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
11. Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Winter Park, FL (PRWEB) May 23, 2013 ... 7 Day Belly Blast Diet to determine what makes ... diets. , The published review highlights three main components ... metabolic rate; achieving a positive mindset and the personal ... change calorie intake every 7 days to keep the ...
(Date:5/23/2013)... Denise Mann HealthDay Reporter , , THURSDAY, May ... Americans take to help treat hip and knee osteoarthritis ... risk for developing glaucoma, a small new study of ... is an increase of intraocular pressure (IOP) or pressure ... the leading causes of blindness. In ...
(Date:5/23/2013)... Memorial Day Focus Spotlight on Military ... a part of the U.S. Military for more than ... it, these men and women will be honored for ... America. As veterans transition to civilian life, there ... workplace chaplaincy world. , Marketplace Chaplains, America’s original ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 “Talk. They ... campaign that empowers parents to talk to children as ... underage drinking, was launched today by the Substance Abuse ... kickoff occurred in conjunction with SAMHSA’s 2013 National Prevention ... and action around, substance abuse and mental health issues. ...
(Date:5/23/2013)... dragged to its destruction inside a cell, a ... that thwart the development of tumor-suppressing microRNAs (miRNAs) ... online publication at Nature . , Under ... the epidermal growth factor receptor (EGFR) gums up ... by scientists at The University of Texas MD ...
Breaking Medicine News(10 mins):Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3
... provides important new alternative for patientsRESEARCH TRIANGLE PARK, N.C., ... announced today that the U.S. Food and Drug Administration ... Lamictal ODT uses a novel drug-delivery formulation ... has a pleasant taste and disintegrates on the tongue. ...
... GRAND RAPIDS, Mich., May 11 Lambert, ... Aspirus, Inc. to its growing roster of health care ... Wausau, Wis. providing health care services to residents in ... Aspirus Wausau Hospital is consistently recognized as one ...
... jointly announce a strategic alliance created to provide clients with contract ... ... and Chennai, India (PRWEB) - Dalton Pharma Services and ProCitius Research ... contract chemistry services of exceptional value. , , , ...
... New HHS Report Released During National Women,s Health Week ... A new report released today on gender-based differences in ... as men to suffer from major depression. The ... including the effect trauma and violence can have on ...
... more likely than men to feel the pinch of ... half (52%) of working-age women reporting problems accessing needed ... men, a new Commonwealth Fund study finds. Women who ... 69 percent of underinsured women have problems accessing care ...
... neck injuries , , SUNDAY, May 10 (HealthDay News) -- ... neck injuries related to recreational or work activities outdoors, ... States, about 1.5 million people are treated in hospital ... treated for neck fractures, according to the Consumer Product ...
Cached Medicine News:Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 2Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 3Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 4Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 5Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 6Health News:Lambert, Edwards & Associates Named Agency of Record for Aspirus, Inc. 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 3Health News:Women at Greater Risk for Depression and Anxiety 2Health News:Women at Greater Risk for Depression and Anxiety 3Health News:7 of 10 women are uninsured or underinsured, or have medical bill, debt, access problems 2Health News:7 of 10 women are uninsured or underinsured, or have medical bill, debt, access problems 3Health News:Ladders, Swings and More Can Cause Peril 2
(Date:5/23/2013)... May 23, 2013  The need to add ... continuum was highlighted prominently at the 108 th ... (AUA), in San Diego.  According to SonaCare Medical, ... ultrasound (HIFU) technology, the need for image-guided technologies ... urologists to consider minimally invasive ablative treatments, was ...
(Date:5/23/2013)... MILFORD, Mass. , May 23, 2013  Spring ... for the treatment of viral infections, today announced that ... of SB 9200, its investigational, once daily, oral therapy ... conducted in healthy, HCV-infected patients and is designed to ... 9200. SB 9200 is a first-in-class drug for the ...
(Date:5/23/2013)... , May 23, 2013 Israel ... Israel 2013 , Israel,s 1 st ... October 14 th -15 th in Tel ... most innovative city in the world by the Wall ... BrainTech Israel 2013 will showcase the latest breakthroughs ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... director of the Huntington Hospital Cancer Center, performed the first ... week. In a typical resection there are three ports ... across the belly in an open procedure. , ... offer shorter lengths of stay, less pain and quicker return ...
... from a pivotal trial suggests that ofatumumab has activity ... , , , ... Genmab A/S (OMX: GEN) announced today positive results from ... in the treatment of refractory chronic lymphocytic leukemia (CLL). ...
Cached Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
Medicine Products: